SynthesisBioscience reports2020
Comparison of diagnostic accuracy of Midkine and AFP for detecting hepatocellular carcinoma: a systematic review and meta-analysis.
Synthesis in Bioscience reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 50 citations in OpenAlex.
- Case Report: Serum AKR1B10 as a complementary marker for the detection of AFP-negative hepatocellular carcinoma - a report of two cases.Frontiers in medicine · 2026Article
- Serum Proteomic Profile Based on the TGF-β Pathway Stratifies Risk of Hepatocellular Carcinoma.Liver international : official journal of the International Association for the Study of the Liver · 2025Article
- Multi-omics integration of TPX2 in prognostic prediction in resectable hepatocellular carcinoma.Discover oncology · 2025Article
- New insights into biomarkers and risk stratification to predict hepatocellular cancer.Molecular medicine (Cambridge, Mass.) · 2025Review
- Current Advancements in Serum Protein Biomarkers for Hepatitis B Virus-Associated Hepatocyte Remodeling and Hepatocellular Carcinoma.Immunity, inflammation and disease · 2025Review
- High Midkine Expression Correlates with Poor Prognosis and Immune Cell Infiltration in Hepatocellular Carcinoma.International journal of general medicine · 2025Article
- Construction and evaluation of a liver cancer risk prediction model based on machine learning.World journal of gastrointestinal oncology · 2024Article
- RNA Interference based Midkine Gene Therapy for Hepatocellular Carcinoma.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- PPIH acts as a potential predictive biomarker for patients with common solid tumors.BMC cancer · 2024Article
- Prognostic and diagnostic effects of high serum midkine levels in patients with hepatocellular carcinoma.Oncology letters · 2024Article
- Serum Aldo-Keto Reductase Family 1 Member B10 (AKR1B10) as a Potential Biomarker for Diagnosis of Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2024Article
- Review
- Updating the Clinical Application of Blood Biomarkers and Their Algorithms in the Diagnosis and Surveillance of Hepatocellular Carcinoma: A Critical Review.International journal of molecular sciences · 2023Review
- VOCs from Exhaled Breath for the Diagnosis of Hepatocellular Carcinoma.Diagnostics (Basel, Switzerland) · 2023Article
- Article
- Differential proteomic analysis of plasma-derived exosomes as diagnostic biomarkers for chronic HBV-related liver disease.Scientific reports · 2022Article
- Exhaled volatile organic compounds for diagnosis of hepatocellular carcinoma.Scientific reports · 2022Article
- The Diagnostic Value of Contrast-Enhanced Ultrasound and Enhanced CT Combined with Tumor Markers AFP and CA199 in Liver Cancer.Journal of healthcare engineering · 2022Article
- Current and Emerging Tools for Hepatocellular Carcinoma Surveillance.Hepatology communications · 2021Review
- Proteomic Profiling and Artificial Intelligence for Hepatocellular Carcinoma Translational Medicine.Biomedicines · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveMidkine (MDK) has been proposed as one of the most promising markers for hepatocellular carcinoma (HCC). This meta-analysis was conducted to compare the diagnostic accuracy of MDK and α-fetoprotein (AFP) for HCC.
methodsWe systematically searched PubMed/MEDLINE, Ovid/EMBASE, and the Cochrane Library for all relevant studies up to 18 May 2019. The Revised Quality Assessment for Studies of Diagnostic Accuracy tool (QUADAS-2) was used to assess the methodological quality of the included studies. The sensitivity, specificity, and the area under the curve (AUC) of MDK and AFP for detecting HCC were pooled using random-effects model.
resultsSeventeen studies from five articles with a total of 1122 HCC patients and 2483 controls were included. The summary estimates using MDK and AFP for detecting HCC were as follows: sensitivity, 85 vs 52%, specificity, 82 vs 94%, and AUC, 0.90 vs 0.83. The summary estimates using MDK and AFP for detecting hepatitis virus-related HCC as follows: sensitivity, 93 vs 74%, specificity, 85 vs 97%, and AUC, 0.95 vs 0.97. The summary estimates using MDK and AFP for detecting early-stage HCC were as follows: sensitivity, 83.5 vs 44.4%, specificity, 81.7 vs 84.8%, and AUC, 0.87 vs 0.52. The summary estimates using MDK for detecting AFP-negative HCC as follows: sensitivity, 88.5%, specificity, 83.9%, and AUC, 0.91.
conclusionMDK is more accurate than AFP in diagnosing HCC, especially for early-stage HCC and AFP-negative HCC. Both MDK and AFP had excellent diagnostic performance for hepatitis virus-related HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.